Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, drawn from the whole corpus: 7 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether temozolomide can replace PCV without losing survival (CODEL).
How to sequence vorasidenib, chemotherapy and radiotherapy over a disease course of decades.
Late cognitive effects of radiotherapy in long survivors.
No effective treatment for the rare tumours that acquire CDKN2A/B loss or hypermutation.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12 (INDIGO): first targeted therapy for low-grade glioma
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12
A milestone in how this cancer is treated.
PFS 27.
A milestone in how this cancer is treated.